ONDQA Division Director
Blair Fraser replaces Acting Director Chi-wan Chen as Office of New Drug Quality Assessment Division Director-Pre-Marketing Assessment I. Fraser, who will continue to serve as acting chief of Branch II until a replacement is found, has recently been engaged in issues regarding follow-on protein products and implementation of quality-by-design into CMC. Chen will continue to serve as deputy director of ONDQA...
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.